These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 22985614

  • 1. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor and thrombomodulin levels in children with hypothyroidism.
    Alioğlu B, Kılıç N, Şimşek E, Dallar Y.
    J Clin Res Pediatr Endocrinol; 2012 Sep; 4(3):146-50. PubMed ID: 22985614
    [Abstract] [Full Text] [Related]

  • 2. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.
    Erem C, Ucuncu O, Yilmaz M, Kocak M, Nuhoglu I, Ersoz HO.
    Endocrine; 2009 Feb; 35(1):75-80. PubMed ID: 18958631
    [Abstract] [Full Text] [Related]

  • 3. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N, Guldiken S, Demir M, Tugrul A.
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
    [Abstract] [Full Text] [Related]

  • 4. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
    Erem C, Nuhoglu I, Yilmaz M, Kocak M, Demirel A, Ucuncu O, Onder Ersoz H.
    J Endocrinol Invest; 2009 Feb; 32(2):169-74. PubMed ID: 19411818
    [Abstract] [Full Text] [Related]

  • 5. Elevated thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels in overt and subclinical hypothyroid patients were reduced by levothyroxine replacement.
    Akinci B, Comlekci A, Ali Ozcan M, Demir T, Yener S, Demirkan F, Yuksel F, Yesil S.
    Endocr J; 2007 Feb; 54(1):45-52. PubMed ID: 17090955
    [Abstract] [Full Text] [Related]

  • 6. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
    Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O.
    Eur J Endocrinol; 2009 May; 160(5):863-8. PubMed ID: 19233920
    [Abstract] [Full Text] [Related]

  • 7. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism.
    Erem C, Ucuncu O, Yilmaz M, Kocak M, Nuhoglu İ, Ersoz HO.
    Endocrine; 2009 Dec; 36(3):473-8. PubMed ID: 19859836
    [Abstract] [Full Text] [Related]

  • 8. Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI.
    Erem C, Nuhoglu I, Kocak M, Yilmaz M, Sipahi ST, Ucuncu O, Ersoz HO.
    Endocrine; 2008 Jun; 33(3):270-6. PubMed ID: 19016004
    [Abstract] [Full Text] [Related]

  • 9. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
    Akinci B, Comlekci A, Yener S, Demir T, Ozcan MA, Bayraktar F, Yesil S.
    Endocr J; 2007 Aug; 54(4):593-9. PubMed ID: 17690487
    [Abstract] [Full Text] [Related]

  • 10. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation.
    Watanabe R, Wada H, Watanabe Y, Sakakura M, Nakasaki T, Mori Y, Nishikawa M, Gabazza EC, Nobori T, Shiku H.
    Thromb Res; 2001 Oct 01; 104(1):1-6. PubMed ID: 11583733
    [Abstract] [Full Text] [Related]

  • 11. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
    Zorio E, Castelló R, Falcó C, España F, Osa A, Almenar L, Aznar J, Estellés A.
    Br J Haematol; 2003 Sep 01; 122(6):958-65. PubMed ID: 12956767
    [Abstract] [Full Text] [Related]

  • 12. Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study.
    Bladbjerg EM, Madsen JS, Kristensen SR, Abrahamsen B, Brixen K, Mosekilde L, Jespersen J.
    J Thromb Haemost; 2003 Jun 01; 1(6):1208-14. PubMed ID: 12871321
    [Abstract] [Full Text] [Related]

  • 13. Effect of levothyroxine suppression therapy on plasma thrombin activatable fibrinolysis inhibitor antigen levels in benign thyroid nodules.
    Akinci B, Demir T, Comlekci A, Yener S, Ozcan MA, Karaoglu O, Yuksel F, Secil M, Yesil S.
    Med Princ Pract; 2011 Jun 01; 20(1):23-8. PubMed ID: 21160209
    [Abstract] [Full Text] [Related]

  • 14. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.
    Yener S, Akarsu M, Demir T, Akinci B, Sagol O, Bayraktar F, Ozcan MA, Tankurt E, Yesil S.
    J Endocrinol Invest; 2007 Nov 01; 30(10):810-9. PubMed ID: 18075282
    [Abstract] [Full Text] [Related]

  • 15. Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon.
    Binette TM, Taylor FB, Peer G, Bajzar L.
    Blood; 2007 Nov 01; 110(9):3168-75. PubMed ID: 17644733
    [Abstract] [Full Text] [Related]

  • 16. Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease.
    Yüzbaşıoğlu B, Ustaoğlu M, Yüzbaşıoğlu Ş, Akbulut UE, Özdil K.
    Turk J Gastroenterol; 2019 Dec 01; 30(12):1025-1029. PubMed ID: 31854307
    [Abstract] [Full Text] [Related]

  • 17. Postprandial thrombin activatable fibrinolysis inhibitor and markers of endothelial dysfunction in type 2 diabetic patients.
    Rigla M, Wägner AM, Borrell M, Mateo J, Foncuberta J, de Leiva A, Ordóñez-Llanos J, Pérez A.
    Metabolism; 2006 Nov 01; 55(11):1437-42. PubMed ID: 17046544
    [Abstract] [Full Text] [Related]

  • 18. The effect of hormone replacement treatment on thrombin-activatable fibrinolysis inhibitor activity levels in patients with Hashimoto thyroiditis.
    Cetinkalp S, Tobu M, Karadeniz M, Buyukkeçeci F, Yilmaz C.
    Intern Med; 2009 Nov 01; 48(5):281-5. PubMed ID: 19252348
    [Abstract] [Full Text] [Related]

  • 19. Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis.
    Miljić P, Heylen E, Willemse J, Djordjević V, Radojković D, Colović M, Elezović I, Hendriks D.
    Srp Arh Celok Lek; 2010 Jan 01; 138 Suppl 1():74-8. PubMed ID: 20229688
    [Abstract] [Full Text] [Related]

  • 20. Thrombin Activable Fibrinolysis Inhibitor in Beta Thalassemia.
    Chhikara A, Sharma S, Chandra J, Nangia A.
    Indian J Pediatr; 2017 Jan 01; 84(1):25-30. PubMed ID: 27487812
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.